Kornimate/medical-research-clean huggingface dataset:
effects of low-intensity transcranial magnetic stimulation on major depressive disorder, and on 5-hydroxyindoleacetic acid and brain-derived neurotrophic factor levels

Conditions: Depression - Major Depressive Disorder; Transcranial Magnetic Stimulation; Placebo

Summary: the goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (tms) on major depressive disorder (mdd) and on the levels of 5-hydroxyindoleacetic acid (5-hiaa) and brain-derived neurotrophic factor (bdnf). tms works to treat mdd by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder. final metabolites of serotonin such as 5-hiaa and growth factors such as bdnf will also be studied before starting the intervention and at the end to check if there is a significant change in their concentration. likewise, its safety will be evaluated by monitoring the symptoms that they present at the end of the intervention and one month later. the main questions that are intended to be answered are: * does low-intensity tms reduce depressive symptoms in patients with mdd? * does low-intensity tms significantly change the initial and final concentrations of 5-hiaa and bdnf? * what adverse effects might patients who are exposed to low-intensity tms experience? the researchers will compare low-intensity and accelerated tms with sham tms to see if low-intensity tms works to treat mdd. participants: * will undergo an initial clinical assessment to confirm the disorder, comorbidities, and general health status. * a 5 ml blood sample will be taken before starting the intervention. * low-intensity tms will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 millitesla (mt) and frequency of 50 hz in theta bursts. symptoms will be monitored daily. * a 5 ml blood sample will be taken at the end of the intervention and general health status clinimetrics will be reapplied.


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years. * both sexes. * those who have a diagnosis of mdd previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes). * those who continue with their respective treatment and attend follow-up consultations at the health facility. * those who do not have a history of epilepsy, schizophrenia, neurosurgeries. * those who do not have metal plates anywhere in the skull, neck, chest and shoulder. * those who do not use pacemakers. * those who do not take hormone substitutes. * those who agree to participate in the research. exclusion criteria: * those who are pregnant.

Keywords: accelerated low-intensity transcranial magnetic stimulation major depressive disorder depression brain-derived neurotrophic factor 5-hydroxyindoleacetic acid
efficacy of sprayable peg barrier in gynecologic laparoscopy

Conditions: Postoperative Adhesion; Peritoneal Adhesion, Nos

Summary: the purpose of the study is to investigate whether sprayable peg barrier is effective in reducing adhesions in laparoscopic gynecologic surgery.


Eligibility criteria:
inclusion criteria: * \>18 years * undergoing gynecologic laparoscopy exclusion criteria: * suspected malignancy * incomplete adhesiolysis during initial laparoscopy * pregnancy * lactating * stage iv endometriosis

Keywords: tissue adhesions laparoscopy
healthy eating & active living for diabetes in primary care networks

Conditions: Type 2 Diabetes

Summary: the investigators aim to establish the effectiveness of a prescribed, community-based lifestyle modification program for those with recently diagnosed diabetes. the investigators hypothesize that those who enter a 6 month program will report greater levels of physical activity compared to a group who do not enter the program but who continue to receive usual care.


Eligibility criteria:
inclusion criteria: * adult, recent type 2 diabetes diagnosis according to a diabetes patient registry, received a referral to a group-based lifestyle program or some provider-based diabetes related education. exclusion criteria: * physical limitation, cardiovascular contraindication, participation in any other research study
climat impact on urinary iodine concentration

Conditions: Iodine Deficiency

Summary: urinary iodine concentration (uic) is the recommended biomarker of iodine status in populations. yet, the influence of climate on uic remains unclear. hot climate may reduce urine volume and consequently increase uic independent of iodine status. this could lead to an overestimation of population iodine intake, thus masking iodine deficiency in vulnerable groups. in this longitudinal observational cohort study in women of reproductive age we will collect 24h and spot urine samples in the summer and winter season. the influence of high temperature climates on uic, measured and estimated urinary iodine excretion will be estimated.


Eligibility criteria:
* female * non-pregnant and non-lactating * general good health, assessed by no reported treatment for chronic disease * non-smoking * no known history of major medical illnesses or thyroid dysfunction as well as gastrointestinal or metabolic disorders and taking no chronic medication * residence at the respective study site for 12 months or longer and no plans of moving away during the study year. * no use of iodine containing dietary supplements during the last 6 months * no use of x-ray / ct contrast agent or iodine containing medication within the last year * no use of iodine containing disinfectants during the last 6 months * participants should be between 18 and 49 years at date of enrollment

Keywords: urinary iodine concentration
magnetic stimulation of the human nervous system

Conditions: Demyelinating Disease; Healthy; Lysosomal Storage Disease; Motor Neuron Disease; Movement Disorder

Summary: transcranial magnetic stimulation (tms) is a non-invasive technique to gather information about brain function. it is very useful when studying the areas of the brain related to motor activity (motor cortex, corticospinal tract, spinal cord and nerve roots). the procedure is conducted by transmitting a magnetic signal into the brain to stimulate an area of the body. electrodes (small pieces of metal taped to areas of the body) are used in order to measure electrical activity. a magnetic signal is sent from a metal instrument held close to the patient's head, to an area of the brain responsible for motor activity of a certain area of the body. the electrodes pick up and record the electrical activity in the muscles. this study will employ the use of tms to diagnose neurological disorders that affect the motor cortex or the corticospinal tract. normal subjects are sometimes studied to investigate normal activity of the nervous system and to train doctors in clinical neurophysiology and electrodiagnostic medicine at the national institutes of health (nih).

this protocol outlines the use of magnetic stimulation as a diagnostic tool in patients with suspected dysfunction of central motor pathways or nerve roots and as a tool to localize and characterize suspected corticospinal abnormalities in neurologic disorders and systemic disorders with neurological manifestations. the protocol is intended for clinical use. transcranial magnetic stimulation has been used for diagnosis of neurologic disorders since 1987. the principles of magnetic stimulation and its use for diagnosis are described in current textbooks of clinical neurophysiology as a routine procedure and should be included in the training program for fellows in clinical neurophysiology and electrodiagnostic medicine at nih. the magnetic stimuli are to be given as single or paired pulses at repetition rates less than 1 per second.

Eligibility criteria:
inclusion criteria: adult patients with weakness or motor dysfunction. children and adolescents with corticospinal tract signs. normal volunteers, adults. normal volunteers, children aged 4-17. exclusion criteria: pregnant women. subjects with implanted devices: pacemakers, medication pumps or defibrillators. subjects with metal in the cranium except the mouth. subjects with intracardiac lines. normal subjects with history of seizures.

Keywords: myelopathy demyelination leukodystrophy motor neuron disease movement disorders normal volunteer
transcranial treatments in eating disorders

Conditions: Anorexia Nervosa; Bulimia Nervosa

Summary: the primary aim of this study is to study how repetitive transcranial magnetic stimulation (rtms) tailored to specific anorexia nervosa (an) or bulimia nervosa (bn) brain activation alterations will promote recovery and to study how inhibitory tdcs (transcranial direct current stimulation) will reduce symptoms of body image distortion in a second sample of an and bn groups.


Eligibility criteria:
inclusion criteria: * anorexia nervosa subjects: * meets dsm-5 criteria for anorexia nervosa (an) either binge-eating/purging type or restricting-type: * intense fear of gaining weight or becoming fat, even though underweight. * the ability to undergo an mri, fmri or other similar procedure requiring spending time in an enclosed space * bulimia nervosa subjects: * meet dsm-5 criteria for bulimia nervosa (bn): * self-induced vomiting; misuse of laxatives, diuretics, enemas, medication, fasting, excessive exercise. exclusion criteria: * electrolyte, blood count or kidney or liver function abnormalities. * no symptoms of alcohol or other substance abuse or dependence in the past 3 months, * no previous or current organic brain syndromes, dementia, psychotic disorders, somatization disorders, or conversion disorder, head trauma, indication of mental retardation or pervasive developmental disorder. * no antipsychotics, tricyclic antidepressants or wellbutrin or other medication that may lower the seizure threshold. * claustrophobia.
intervention for the elderly with malnutrition, hidden hunger and low skeletal muscle mass

Conditions: Malnutrition Risk in Elder

Summary: background: as the aging of the population aggravating, the ratio of the elderly in empty nest family has reached 50%, particularly in big and medium size cities, it is as high as 70%. the elderly in those families where no child living inside, elderly living alone, including an individual living alone or living with spouse are known as empty nester. the diversity of food consumption of empty nester is always poor, with single and simple meals, especially for the consumption of "core food" (fish, meat, egg, milk, vegetables and fruits), and the quantity and variety of consumption is very limited, which make the elderly be prone to be deficient of high quality protein and micronutrient. in 2005, the world health organization (who) brought up a new concept for the universally exiting problem of vitamin and trace elements intake deficiency among people, namely hidden hunger. with age increasing, multiple causes such as single eating pattern, empty nest lifestyle and chronic diseases lead to long term intake deficiency of protein and micronutrient of the elderly, which will further result in various symptoms of nutritional deficiency. therefore, it is particularly important for the empty nester to have sufficient energy, high quality protein and multiple micronutrients to prevent hidden hunger and sarcopenia, thus avoiding the health problem and life quality decreasing caused by them.


Eligibility criteria:
inclusion criteria: 1. the one who is or is between 65 to 85 years old, male or female; 2. the one with nutritional risk according to mna-short form evaluation (score less than12); 3. the one who has low skeletal muscle mass (with bioelectrical impedance analysis report indicating that the skeletal muscle mass is less than 90% of the normal level) and/or the one who has at least 1 type of the micronutrient deficiency symptom (part a \< 40 or part a \< 85 in the hidden hungry evaluation questionnaire) exclusion criteria: 1. long-term bedridden or the one has difficult in taking food orally; 2. liver failure in recent one year; 3. renal insufficiency (serum creatinine is more than 2 times of normal value) 4. the one who is allergic to or not applicable to the component in oral dietary supplement; 5. the one with parkinsonism, epilepsy and other nervous system disorders; 6. malignant tumor patients with chemotherapy and chemotherapy; 7. irritable bowel disease and other chronic wasting diseases. 8. taking multi-vitamin\&mineral supplements or protein or other oral nutritional supplements
united kingdom (uk) patient preference study of somatuline autogel and treatment administration setting

Conditions: Neuroendocrine Tumours (NET)

Summary: the aim of the study is to generate real-world evidence to describe the patient experience of administration of somatuline® autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (hrqol)


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of gep-nets * patients on prescribed lanreotide autogel®; * patients who have switched from hospital to homecare administration setting at least 2 months ago * patients judged to be on a stable dose; 120mg for tumour control or \>1 injection at same dose for symptom control exclusion criteria: * patients who decline or lack capacity to consent to participate in the study
adiponectin and asymmetric dimethylarginine (adma) level in type-2 diabetes patients after 12 weeks of treatment with glimepiride and metformin fixed dose combination

Conditions: Diabetes Mellitus, Type 2

Summary: primary objective: to evaluate the change in plasma levels of adiponectin and asymmetric dimethylarginine (adma) in type 2 diabetes patients after 12 weeks of treatment with amaryl-m secondary objectives: 1. to assess the role of amaryl-m in the change of plasma levels of adiponectin and adma in type 2 diabetes patients after 8 weeks of therapy 2. to evaluate the brachial-ankle pulse wave velocity (bapwv) change after 8 and 12 weeks of therapy with amaryl-m 3. to evaluate the efficacy of amaryl-m in the improvement of patients glycemic level (fasting blood glucose (fbg) and glycosylated hemoglobin (hba1c)) 4. to evaluate the change of tumor necrosis factor - alfa (tnf-alfa) after 12 weeks of therapy with amaryl-m 5. to evaluate the homeostatic model assessment of insulin resistance (homa-ir) change after 12 weeks of therapy with amaryl-m 6. to evaluate the homa-β change after 12 weeks of therapy with amaryl-m 7. to evaluate the relationship between adiponectin and adma level with fbg or hba1c level

the clinical trial will consist of 2 weeks of selection followed by a 12 weeks (3 months) of treatment period.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus patients * patients with hba1c \>or= 7.0% and \< 10.0% * patients not currently treated with any oral antidiabetic drugs (oads) exclusion criteria: * participation in other investigational clinical trial * current temporary insulin treatment: gestational diabetes, pancreas cancer, surgery etc. * women who are pregnant and lactating * type 1 diabetes mellitus patients * treatment with antihypertensive angiotensin-converting enzyme (ace)-inhibitors and/or angiotensin ii receptor blocker (arb) or has just stopped treatment for less than two months * treatment with lipid lowering agent statins or has just stopped treatment for less than two months * known hypersensitive to any of the excipients of amaryl-m, sulphonylureas, sulfonamides or biguanide * patients with active smoking or history of smoking cessation less than 2 months * patients with history of severe hepatic dysfunction * patients with serum creatinine \>or= 1.5 mg/dl (male) and \>or= 1.4 mg/dl (female) * patients with congestive heart failure requiring pharmacologic treatment * treatment with antifungal agent especially miconazole the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
the role of music in palliative care: a proposal for a rural based initiative in music based interventions

Conditions: Improved Emotional Regulation; Improvement in Quality of Life; Symptom Relief; Preservation of Dignity; Existential Solace; Relief of Suffering; Emotional Regulation; Quality of Life; Dignity

Summary: current practice in larger palliative care centers offer many supportive service modalities, which are often unavailable in the rural setting. music therapy by experienced registered music therapists is an example of such a modality. the current evidence continues to grow, identifying music therapy's benefits to help with symptom relief as well as to improve quality of life in many aspects of medicine, but especially in the context of palliative care. this proposal outlines an initiative to provide music-based interventions in a rural community palliative care unit where there is limited availability to a registered music therapist.

study participants in the pilot phase will include patients admitted to the aberdeen hospital palliative care unit. patients excluded from participating would include those unwilling to participate for any reason. all patients will be invited to complete the mcgill quality of life questionnaire - revised (mcgill qol-r) upon admission to the unit. the questionnaire will not be part of the permanent medical record and the participants will remain anonymous. afterwards participants will be asked if they would like to listen to music during their stay in the hospital. music will be selected according to their choices from an i-tunes playlist. participants will be invited to listen to music at their own discretion. prior to discharge from the hospital or after 3 days all willing patients will be again invited to complete the mcgill qol-r questionnaire. the participants will remain anonymous, but will be identified as to whether they listened or did not listen to music during their hospitalization.

Eligibility criteria:
inclusion criteria: * patients admitted to the aberdeen hospital palliative care unit. exclusion criteria: * those patients unwilling to participate for any reason
fentanyl and clonidine for analgesia during hypothermia in term asphyxiated infants

Conditions: Asphyxia Neonatorum

Summary: a prospective pharmacokinetic (pk), pharmacodynamic (pd) and pharmacogenetic (pg) observation study, including the pk/pd/pg relationship, in fentanyl and clonidine administered for analgesia and sedation to term newborn asphyxiated infants receiving hypothermic treatment in the nicu.

all patients that are admitted to the study neonatal intensive care units (nicus) for hypothermic treatment due to perinatal asphyxia are potential study patients, and their parents will be asked for consent. the patient will be treated according to clinical guidelines and will be included in the study if in need for fentanyl and clonidine according to clinical judgment (hie and pain scores) and as decided by the responsible clinical doctor. the dosing and administration of the drugs will be implemented according to an algorithm based on pain scoring results. apart from extra blood sampling, the bedside monitoring, investigations (electroencephalography (eeg), echocardiography (ecg), ultrasound of the brain and magnetic resonance imaging, (mri)) and follow-up (neurologic examination) are the same as for all infants receiving hypothermia according to national and international guidelines. a brief standardised pain stimulation will be performed as part of the pain and stress assessment. in total 50 infants will be included.

Eligibility criteria:
inclusion criteria: * term infants (≥ gw 36+0) who, according to national guidelines (6), will receive hypothermic treatment following perinatal asphyxia, and are in need for analgesic or sedative medication according to clinical judgment based on thomsons score and alps-neo. * existing arterial or venous cannulas/catheters for repeated non-traumatic blood sampling * informed and written parental consent. exclusion criteria: * atrioventricular (av)- block i-iii or heart rate \< 70 . * serious coronary heart disease with need for postnatal surgery * mean arterial blood pressure \<35 mmhg despite adequate treatment.

Keywords: term infants analgesia fentanyl clonidine pharmacokinetics sedation pharmacodynamics neurophysiology pharmacogenetics asphyxia hypothermia
involvement of ffa metabolism and insulin resistance in cardiac death

Conditions: Kidney Disease; Coronary Artery Disease; Hemodialysis

Summary: the investigators evaluated predictive values of myocardial fatty acid metabolism and insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries.

dialysis patients have extraordinarily high mortality rates. cardiac diseases play an important role in deaths among end-stage renal disease (esrd) patients undergoing renal replacement therapy. previous studies have shown that maintenance hemodialysis patients have high prevalence of obstructive coronary artery disease. while obstructive coronary artery disease is undoubtedly involved in cardiac deaths induced by acute myocardial infarction or congestive heart failure and in sudden cardiac death, cardiac death can occur in hemodialysis patients who have apparently no pre-existing obstructive coronary artery disease. however, few studies have investigated the factors which are useful for stratifying the risk of cardiac death in dialysis patients with normal coronary arteries. we recently showed that visualizing severely impaired myocardial fatty acid metabolism on images can help not only to detect obstructive coronary artery disease \[8\], but also to identify patients at high risk of cardiac death among hemodialysis patients without coronary intervention or old myocardial infarction and among those with coronary revascularization by percutaneous coronary artery intervention. in addition, combination of impaired cardiac fatty acid metabolism with insulin resistance, which is one of the risk factors related with coronary atherosclerosis, may contribute to left ventricular dysfunction in patients with maintenance hemodialysis with normal coronary arteries. impaired myocardial fatty acid metabolism and insulin resistance, both of which reduce the synthesis of myocardial adenosine triphosphate (atp), are likely to be involved in fatal cardiac events by causing deficiency of myocardial energy supply. in this study, we prospectively investigated the potential of myocardial fatty acid metabolism and insulin resistance to predict cardiac death in hemodialysis patients without pre-existing obstructive coronary artery disease.

Eligibility criteria:
inclusion criteria: * hemodialysis patients who had normal coronary arteries identified by coronary angiography and underwent the examination of bmipp spect and measurement of homa-ir as a parameter of insulin resistance. exclusion criteria: * patients who had not done bmipp spect within one month of coronary angiography * congestive heart failure (nyha 3-4) * significant valvular heart disease * pacemaker * idiopathic cardiomyopathy * malignancy * patients who had not measured homa-ir within one month after coronary angiography * patients receiving extrinsic insulin or medication of sulfonylurea

Keywords: fatty acid metabolism insulin resistance cardiac death hemodialysis normal coronary arteries predictive values of impaired myocardial fatty acid metabolism or insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries